Weiss Ratings Reaffirms Sell (D-) Rating for Bioventus (NASDAQ:BVS)

Key Points

• Weiss Ratings has reaffirmed a "sell (D-)" rating for Bioventus (NASDAQ:BVS), indicating a negative outlook from the firm's analysts.
• In contrast, Wall Street Zen upgraded Bioventus from a "buy" to a "strong-buy" rating, illustrating mixed sentiments among analysts about the stock's performance.
• Bioventus shares closed at $6.94 on Friday, with a market capitalization of $573.80 million and reported revenue of $98.59 million in its last quarterly earnings.

Bioventus (NASDAQ:BVS - Get Free Report)'s stock had its "sell (d-)" rating restated by stock analysts at Weiss Ratings in a research report issued on Friday,Weiss Ratings reports.

Separately, Wall Street Zen raised Bioventus from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of "Sell".

Bioventus Trading Down 0.3%

Shares of BVS traded down $0.02 during trading hours on Friday, hitting $6.94. 148,039 shares of the stock traded hands, compared to its average volume of 376,745. The company has a quick ratio of 0.96, a current ratio of 1.48 and a debt-to-equity ratio of 1.48. Bioventus has a 1-year low of $5.81 and a 1-year high of $14.38. The stock has a market capitalization of $573.80 million, a price-to-earnings ratio of 14.22 and a beta of 0.81. The firm has a fifty day simple moving average of $7.02.

Bioventus (NASDAQ:BVS - Get Free Report) last issued its quarterly earnings results on Thursday, March 10th. The company reported $2.32 earnings per share (EPS) for the quarter. Bioventus had a positive return on equity of 23.04% and a negative net margin of 0.03%.The business had revenue of $98.59 million for the quarter.

About Bioventus

Bioventus Inc a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.